A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. - Wikidata - awgldk - TriplyDB

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

http://www.wikidata.org/entity/Q35483796

about

Epigenetic polypharmacology: from combination therapy to multitargeted drugs Multitarget Drugs: an Epigenetic Epiphany.Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.

P2860

Q28067666-5A3CECB8-26DB-4820-BC87-503A78677ADA Q38739347-D89F4F95-F909-45FB-8337-4C76A0E0D5B4 Q54109834-A564F049-7675-4535-B4B5-380DC78299C2

P2860

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

http://www.wikidata.org/entity/Q35483796

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

@ast

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

@en

type

label

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

@ast

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

@en

prefLabel

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

@ast

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

@en

P1433

Q35483796-32705EB9-57E1-4666-873C-5F8E30E87D4F

P1476

Q35483796-382157CE-EC77-4856-8962-FB758EF3138E

P2093

Q35483796-18C367B9-130A-4E49-A6CA-5219F55CE19B

Q35483796-1C0F9C55-717D-423D-9D41-732C40111B92

Q35483796-2AFF1CA3-EB72-415D-AE51-194F8AD01850

Q35483796-3D12B5D7-9755-4E5F-BF8D-5722E100FA0B

Q35483796-4D3738E2-2C47-40CF-BABA-70B9BB5032A7

Q35483796-992E070E-F90E-4F24-8FF9-A637C80B0856

Q35483796-B75D699B-2208-4307-B2EC-524B6314DCBB

Q35483796-C69333B2-E9CC-4FA6-BE08-CA698DC59DB8

Q35483796-CB2E02FF-F5D4-4ED1-BE98-025DE058FDD9

Q35483796-EAB5D0ED-0813-48A7-BE36-DD00F0C5EC1B

P2860

Q35483796-0CA3D3E1-F269-4672-8475-D6BF607C7D6D

Q35483796-0D299DBC-1310-4345-828D-7AE5F704FCD4

Q35483796-0E4459C8-4C85-4B2C-8C31-CA9062AE6685

Q35483796-0EF8149B-F0BA-4837-BC92-549ACB5D0B33

Q35483796-1DBEEBB9-9032-4848-92A0-182B6F5A654C

Q35483796-1EB4E9BA-6BC3-423C-A8FA-6D573E3AE03B

Q35483796-223DBB96-CE13-49FC-B02E-E5490A50D8A4

Q35483796-28B8A029-8136-48E9-8725-4FB9C96F1C19

Q35483796-2EE9C0C1-8E0E-44A0-859F-662174D74D8C

Q35483796-35E29478-AC8D-46D7-8D35-674EB5528D2D

P304

Q35483796-AAAE0603-92E1-455F-9CAB-7035D4E8430B

P31

Q35483796-A71B91A2-DEC9-418A-AC41-929EF8E792E3

P356

Q35483796-48A6861B-0AE6-45F2-99FF-D62AADF9B306

P433

Q35483796-3010118E-2388-4F27-B989-0A4CDC1DC669

P478

Q35483796-2210C348-5CC1-4052-8542-D69DD7BE060F

P50

Q35483796-8DC294F6-6E88-40FB-B157-82A6AD79EC98

Q35483796-C33F3898-595E-438C-9370-7AD5698E9197

P577

Q35483796-41156F14-77C7-417A-B6C7-3BC2B146E018

P5875

Q35483796-A670BF99-8BDA-44EE-B42D-9126133EAC21

P698

Q35483796-4A16F150-E227-423A-B1A3-385ED3044EF1

P932

Q35483796-90B1D898-B9D2-4493-B5CC-546C024B56F0

P356

P1433

EMBO Molecular Medicine

P1476

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

@en

P2093

Chuan Liu

http://www.w3.org/2001/XMLSchema#string

Dianwu Guo

http://www.w3.org/2001/XMLSchema#string

Difei Wang

http://www.w3.org/2001/XMLSchema#string

Hai Jiang

http://www.w3.org/2001/XMLSchema#string

Liya Hong

http://www.w3.org/2001/XMLSchema#string

Michael T Hemann

http://www.w3.org/2001/XMLSchema#string

Wei Wang

http://www.w3.org/2001/XMLSchema#string

Xiaoxi Li

http://www.w3.org/2001/XMLSchema#string

Yajie Wang

http://www.w3.org/2001/XMLSchema#string

Yi Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1

The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage

A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16

The DNA-damage response in human biology and disease

Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks

Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia

How the fanconi anemia pathway guards the genome

The combined status of ATM and p53 link tumor development with therapeutic response

Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase

Structural insight into the regulation of MOF in the male-specific lethal complex and the non-specific lethal complex

P304

438-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15252/EMMM.201404580

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Christian P. Pallasch

P577

2015-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273389844

http://www.w3.org/2001/XMLSchema#string

P698

25759362

http://www.w3.org/2001/XMLSchema#string

P932

4403045

http://www.w3.org/2001/XMLSchema#string